Purification of Eosinophil Granule Basic Proteins. The four proteins, MBP, EPO, ECP, and EDN, that constitute the main basic eosinophil granule basic proteins were purified to physical homogeneity from the eosinophils of patients with hypereosinophilic syndrome as previously described (18) (19) (20) .
Preparation and f 4CJ5-Hydroxytryptamine Loading of Washed
Human Platelets. Freshly drawn platelet-rich plasma from healthy normal adult blood donors was obtained from the Mayo Blood Bank. Platelets were isolated from this platelet-rich plasma as previously described (21) . The washed platelets were resuspended in Tyrode's buffer at a concentration of 2 x 10 8 cells/ml for all studies except those used in the measurement of the secretion of a-N-acetylglucosaminidase (/3-NAGase), where the platelet concentration was 5 x 108 cells/ml. Platelets to be used to assay 5-hydroxytryptamine secretion were loaded with ['°C]5-hydroxytryptamine before resuspension in Tyrode's buffer (21) .
Assay of 5-Hydroxytryptamine, ,B-Thromboglobulin, and ,B-NAcetylglucosaminidase Secretion . For all studies involving measurement of 5-HT secretion, unstirred reaction mixtures containing 100 pl of [14C 15-HT loaded, washed platelets and 15 P.1 of the various eosinophil granule proteins were incubated for 15 min at room temperature. Secretion was terminated by the addition of 15 Ecl of 8% paraformaldehyde, and the reaction was centrifuged to pellet the platelets. Aliquots of the supernatant were counted to quantify5-HT release . Release is reported as a percentage of the total platelet 1"C15-HT, as determined by treatment of the loaded platelets with 2% Triton X-100 . All reactions were performed in duplicate . For studies in which the effect of indomethacin or PGE, on 5-HT secretion was examined, the washed, loaded platelets were treated with freshly prepared 10 p.M indomethacin or 1 uM PGE, for 15 min before stimulation with the eosinophil granule proteins.
For studies measuring the secretion of f3-thromboglobulin (0-TG) and /3-NAGase, the reaction mixtures contained 500 P.l of washed, unloaded platelets and 50 P.1 of eosinophil proteins . The reactions were terminated after 15 min at room temperature by centrifugation through a 1 :1 mixture of Apezion A oil (Biddle Instruments, Blue Bell, PA) and butyl phthalate, since paraformaldehyde is known to interfere with the assay of these components. Aliquots of the resulting aqueous upper layer were then assayed as previously described (22) for 0-TG and ,Q-NAGase using a RIA and a spectrophotometric assay, respectively.
Results and Discussion
When unstirred suspensions of ( 14 C]5-HT loaded, washed human platelets were exposed to purified preparations of the four eosinophil granule proteins, only MBP and EPO evoked the dose-dependent release of 5-HT ( Fig . 1 ) . Both proteins released -60-70% of the total 5-HT with EC50s of 28 and 20 Ag/ml for MBP and EPO, respectively. This release was due to secretion rather than to toxic damage (12, 16, 23) to the platelets because MBP and EPO released only 1% and 4% of the total platelet lactate dehydrogenase under conditions where maximal 5-HT release occurred . In contr4st to the 5-HT secretion evoked by MBP and EPO, neither ECP nor EDN stimulated appreciable secretion of 5-HT This observation suggests that the secretion by MBP or EPO is not simply due to the highly cationic nature of the proteins because ECP and MBP have essentially identical pIs (24) . Furthermore, several pieces of evidence suggest that the secretion mediated by EPO was not due to its enzymatic activity. First, EPO promoted secretion in the absence of exogenously added substrates, hydrogen peroxide, and bromide or iodide. Second, EPO induced the same amount of 5-HT secretion in the presence of 1,100 U/ml of catalase, a concentration of catalase sufficient to degrade any endogenously produced hydrogen peroxide. Finally, heparin, which had no effect on the catalytic activity of EPO, inhibited EPO-dependent secretion, presumably by binding to the EPO. In this regard, the activation of platelets by EPO differs from the EPO mechanism of mast cell activation. Mast cell secretion by EPO has been shown to be absolutely dependent on the enzymatic activity of EPO and required exogenously added hydrogen peroxide and halide (17) . The secretion of 5-HT induced by MBP or EPO was not dependent upon the production of cyclo-oxygenase metabolites of arachidonic acid . As shown in Fig. 2 , the presence of 10 aM freshly prepared indomethacin, a concentration sufficient to inhibit completely platelet thromboxane A2 formation (25) , had no effect on the dose-response curves for 5-HT release mediated by MBP or EPO. Also shown as a control in Fig. 2 is the inefficacy of indomethacin on thrombin- (26, 27) have proposed that platelet agonists can be divided into weak and strong categories . Strong agonists are capable of promoting secretion from unstirred platelet suspensions, and the secretion is independent of thromboxane A2 formation . Based on our observations, both MBP and EPO can be classified as strong platelet agonists.
Although not originally proposed by Detwiler and colleagues as a criterion for strong agonists, several investigators have shown that secretion of lysosomal enzymes is a property restricted to strong agonists (28) . As depicted in shown are the mean ± SEM secretion from the platelets of three independent donors for MBP and thrombin and the mean ± range secretion from the platelets of two independent donors for EPO .
3, MBP promotes the secretion of components of the dense granules, a granules, and lysosomes in a dose-dependent manner. The similarity in extent of secretion and MBP dose requirements for secretion from the dense and a granules, along with the lesser release from lysosomes at higher MBP concentrations, is consistent with the effects reported for other strong platelet agonists (28) . As expected from their failure to induce 5-HT secretion, both EDN and ECP also failed to induce secretion of 0-TG from the a granules (data not shown) .
Although both MBP and EPO can be classified as strong platelet agonists, their mechanism of platelet activation appears to differ from that of other strong platelet agonists based on the effect of PGEI on platelet activation. PGEI is an inhibitor of platelet activation by all known platelet agonists. It is believed to act by increasing the cellular level of c-AMP, which, in turn, activates a c-AMP protein kinase. Activation of this protein kinase results in the phosphorylation of a platelet 1. Gleich protein thought to regulate cytosolic calcium concentrations with the resulting inhibition of platelet granule secretion (29) . As illustrated in Fig . 4 , the strong platelet agonist thrombin can overcome this inhibition at sufficiently high agonist levels. The rightward shift in the secretion dose-response curve in the presence of PGE1 is typical of the effect of PGEI on previously described strong platelet agonists (30, 31) . The effect of 1 p.M PGEI on MBP-and EPO-mediated secretion is, however, quite different . PGEI had relatively little effect on 5-HT secretion at low levels of these agonists but reduced the maximal secretion by 30-50% without shifting the dose curves. Additional studies indicated that high doses of PGEI had no additional effect on secretion (data not shown) . These results suggest that the mechanism of platelet activation by MBP and EPO is distinctly different from that of other strong platelet agonists. Activation of platelets by eosinophil granule proteins may play a role in the pathogenesis of several diseases. The degranulation of eosinophils and subsequent release of granule proteins in the airways may provide a mechanism for the localized activation of extravascular platelets in asthma . Abnormalities of platelet function have been shown in patients with asthma . Also, platelets recovered from the bronchoalveolar lavage fluid from asthmatic patients are often associated with eosinophils and show evidence of degranulation (1, 2). In these patients, MBP has been found deposited on the damaged respiratory epithelium (1, 12, 13) and also recovered in bronchoalveolar lavage fluid (32) and sputum (13) at concentrations consistent with those required for platelet activation found in this study. Platelet activation by MBP and EPO may also be important in other diseases characterized by high levels of eosinophils, such as hypereosinophilia syndrome. This disease is characterized by high levels of blood eosinophils and cardiac involvement associated with the formation of mural thrombi and emboli (4, 5) . MBP is deposited on the endocardium and intima of blood vessels at the sites where thrombus formation almost uniformly occurs (33) . Platelet activation by the deposited MBP may provide an explanation for the close association between eosinophil degranulation and thrombus formation in this disease .
